雌激素受体阳性乳腺癌患者内分泌耐药机制的研究进展

doi:10.13481/j.1671-587x.20170248

[1] GradisharW, Salerno KE. NCCN Guidelines Update:Breast Cancer[J].J Natl Compr Cancer Netw, 2016,14(5 Suppl):641-644.
[2] AndreF, Slimane K, Bachelot T, et al.Breast cancer with synchronous metastases:trends in survival during a 14-year period[J].J Clin Oncol,2004,22(16):3302-3308.
[3] Buzdar AU.Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group[J].J Clin Oncol, 2004,22(15):3199-3200.
[4] Abraham JE, Maranian MJ, Driver KE, et al.CYP2D6 gene variants:association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen[J].Breast Cancer Res,2010,12(4):R64.
[5] Binkhorst L, Mathijssen RH, Jager A, et al.Individualization of tamoxifen therapy:much more than just CYP2D6 genotyping[J].Cancer Treat Rev,2015,41(3):289-299.
[6] Clarke R, Tyson JJ, Dixon JM.Endocrine resistance in breast cancer-An overview and update[J].Mol Cellular Endocrinol, 2015,418 Pt3:220-234.
[7] O'Sullivan CC.Overcoming Endocrine Resistance in-hormone-receptor positive advanced breast cancer-The emerging role of CDK4/6 inhibitors[J].Int J Cancer Clin R,2015,2(4):29.
[8] Ferraldeschi R, Arnedos M, Hadfield KD, et al.Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients[J].Breast Cancer Res Treat, 2012,133(3):1191-1198.
[9] Stephens PJ, Tarpey PS, Davies H, et al.The landscape of cancer genes and mutational processes in breast cancer[J].Nature,2012,486(7403):400-404.
[10] Cardoso F, Costa A, Norton L, et al.ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)[J].Breast, 2014,23(5):489-502.
[11] Parbin S, Kar S, Shilpi A, et al.Histone deacetylases:a saga of perturbed acetylation homeostasis in cancer[J].J Histochem Cytochem, 2014,62(1):11-33.
[12] Yardley DA, Ismail-Khan RR, Melichar B, et al.Randomized phase Ⅱ, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor[J].J Clin Oncol,2013,31(17):2128-2135.
[13] Jordan VC, Curpan R, Maximov PY.Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators[J].J Nat Cancer Inst, 2015,107(6):djv075.
[14] Ma CX, Adjei AA, Salavaggione OE, et al.Human aromatase:gene resequencing and functional genomics[J].Cancer Res,2005,65(23):11071-11082.
[15] Bolden JE, Peart MJ, Johnstone RW.Anticancer activities of histone deacetylase inhibitors[J].Nat Rev Drug Discov, 2006,5(9):769-784.
[16] Hanahan D, Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[17] DeGraffenried LA, Fulcher L, Friedrichs WE, et al.Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway[J].Ann Oncol,2004,15(10):1510-1516.
[18] Kaufman B, Mackey JR, Clemens MR, et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].J Clin Oncol,2009,27(33):5529-5537.
[19] Johnston S, Pippen J, Pivot X, et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol, 2009,27(33):5538-5546.
[20] Yardley DA, Noguchi S, Pritchard KI, et al.Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:BOLERO-2 final progression-free survival analysis[J].Adv Ther, 2013,30(10):870-884.
[21] Bachelot T, Bourgier C, Cropet C, et al.Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study[J].J Clin Oncol, 2012,30(22):2718-2724.
[22] Wolff AC, Lazar AA, Bondarenko I, et al.Randomized phase Ⅲ placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J].J Clin Oncol, 2013,31(2):195-202.
[23] Shapiro GI, Rodon J, Bedell C, et al.Phase Ⅰ safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class Ⅰ PI3K inhibitor, in patients with advanced solid tumors[J].Clin Cancer Res, 2014,20(1):233-245.
[24] Sarker D, Ang JE, Baird R, et al.First-in-human phase Ⅰ study of pictilisib (GDC-0941), a potent pan-class Ⅰ phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors[J].Clin Cancer Res, 2015,21(1):77-86.
[25] Maira SM, Pecchi S, Huang A, et al.Identification and characterization of NVP-BKM120, an orally available pan-class Ⅰ PI3-kinase inhibitor[J].Mol Cancer Ther, 2012,11(2):317-328.
[26] Mauro L, Pellegrino M, Giordano F, et al.Estrogen receptor-alpha drives adiponectin effects on cyclin D1 expression in breast cancer cells[J].FASEB J, 2015,29(5):2150-2160.
[27] Lundgren K, Brown M, Pineda S, et al.Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen:a TransATAC study[J].Breast Cancer Res,2012,14(2):R57.
[28] Giessrigl B, Schmidt WM, Kalipciyan M, et al.Fulvestrant induces resistance by modulating GPER and CDK6 expression:implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex[J].Br J Cancer, 2013,109(10):2751-2762.
[29] Finn RS, Crown JP, Lang I, et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):a randomised phase 2 study[J].Lancet Oncol, 2015,16(1):25-35.
[30] Cristofanilli M, Turner NC, Bondarenko I, et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3):final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J].Lancet Oncol, 2016,17(4):425-439.
[31] Herynk MH, Fuqua SA.Estrogen receptor mutations in human disease[J].Endocr Rev,2004,25(6):869-898.
[32] Toy W, Shen Y, Won H, et al.ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J].Nat Genet,2013,45(12):1439-1445.
[33] Jeselsohn R, Yelensky R, Buchwalter G, et al.Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer[J].Clin Cancer Res,2014,20(7):1757-1767.
[34] Robinson DR, Wu YM, Vats P, et al.Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J].Nat Genet, 2013,45(12):1446-1451.
[35] Andre F, Bachelot T, Commo F, et al.Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer:a multicentre, prospective trial (SAFIR01/UNICANCER)[J].Lancet Oncol, 2014,15(3):267-274.
[36] Robertson JF, Llombart-Cussac A, Rolski J, et al.Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study[J].J Clin Oncol, 2009,27(27):4530-4535.
[37] Di Leo A, Jerusalem G, Petruzelka L, et al.Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J].J Clin Oncol, 2010,28(30):4594-4600.
[38] Robertson JF, Bondarenko IM, Trishkina E, et al.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON):an international, randomised, double-blind, phase 3 trial[J].Lancet,2016,388(10063):2997-3005.

Progress research on mechanism of endocrine resistance in patients with estrogen receptor positive breast cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	. [J]. Journal of Jilin University(Medicine Edition), 2021, 47(4): 1056-1063.
[2]	. Research progress in prevention and treatment of intraoperative and postoperative lymphatic cysts in female patients with malignant tumor pelvic [J]. Journal of Jilin University(Medicine Edition), 2020, 46(04): 888-893.
[3]	SHI Guanghuan, ZHOU Shiping, XU Dongsheng, WANG Xiu. Killing effect of amplified NK cells on gastric cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 530-535.
[4]	ZHU Zhongbo, QIAN Jiansheng, YANG Shuo, LI Kangle, DOU Jianwei. Inhibitory effect of different doses of ¹²⁵I seed implantation on tumor-bearing proliferation in nude mice with breast cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2019, 45(06): 1305-1309.
[5]	. Research progress in clinical application of endocrine therapy for HR+HER2-advanced breast cancer [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 736-741.
[6]	. Research progress in anti-tumor effect and mechanism of photodynamic therapy [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 200-204.
[7]	DENG Ziliang, WANG Sen, LI Peng, XIE Kuilong, LI Shuxian, ZHOU Shixiong, HE Xiaozhou, CHEN Dong, GUO Hongsheng. Enhancement of IL-37 in chemosensitivity of cervical cancer HeLa cells to cisplatin [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 862-866.
[8]	. Advanced research on relationship between tumor microenvironment and radiosensitivity of tumor cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 1038-1044.
[9]	HUANG Xiaodong, LU Qian, SHEN Nan, WANG Yanchun. Inhibitory effects of Alkaline S.chinenis polysaccharides on proliferation and invasion abilities of colon cancer HT-29 cells in vitro [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 287-290.
[10]	QI Yali, ZHAO Dali, LIU Yanjun, GONG Shouliang, WANG Zhicheng. Effects of Akt combined with ionizing radiation onapoptosis, autophagy and proliferation in breast cancer MCF-7 cells [J]. Journal of Jilin University Medicine Edition, 2015, 41(01): 1-5.
[11]	LI Chang-ling,LIN Di,XING Si-ning,ZHAO Song,CHEN Hui-peng,ZHOU Fan,MA Dong-chu. Inhibitory effect of metformin on proliferation of megakaryocytic leukemia cell line Dami and its mechanism [J]. Journal of Jilin University Medicine Edition, 2014, 40(03): 534-538.
[12]	WANG Bo,GU Jun-lian,DAI Yu-xin,TONG Li-jun,MENG Ling-na,LI Yang.  Inhibitory effect of indomethacin combined with radiation on proliferation of human acute myeloid leukemia HL-60 cells [J]. Journal of Jilin University Medicine Edition, 2013, 39(2): 218-221.
[13]	LI Yan-bo,WANG Zhi-cheng\|ZHANG Yan-qiu\|DONG Li-hua,LIU Yang,LI Jin-hua. Effects of TRAIL and endostatin double-gene-radiotherapy on proliferation,cell cycle procession and apoptosis \|in human vascular endothelial \|cells [J]. J4, 2012, 38(4): 611-617.
[14]	ZHANG Mao,JIN Hai-guo, SU Qing-xiu\|BU Ming-wei, LI Yu-ping,LIU Gui-gang . [J]. J4, 2012, 38(4): 784-787.
[15]	QUAN Hai-ying\|WANG Ming-yan\|ZHANG Tong-fei\|GAO Ying\|BAI Yu\|ZHAO Xuan-yi. Mechanism of 3-methyladenine in promoting sensitivity of chemotherapeutics in oral squamous cell carcinoma in vitro [J]. J4, 2012, 38(1): 50-53.